KPV peptide research centers on a remarkably small molecule: a lysine-proline-valine tripeptide (Lys-Pro-Val) corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite its minimal size, KPV has become a focal point in preclinical anti-inflammatory and gastrointestinal-model studies because it appears to retain much of the anti-inflammatory activity of the parent hormone while lacking the pigmentary (melanotropic) effects associated with full-length alpha-MSH. This guide surveys the mechanisms, receptor pathways, and research models scientists have used to examine KPV in vitro and in animal systems.
Research Use Only (RUO): KPV and all peptides discussed here are supplied strictly for laboratory, in-vitro, and preclinical research. They are not for human or veterinary use, are not dietary supplements, and have not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and no human dosing guidance is provided.
What Is KPV? A Fragment of Alpha-MSH
Alpha-MSH is a 13-amino-acid melanocortin peptide derived from proopiomelanocortin (POMC). Researchers established decades ago that much of its anti-inflammatory signaling is concentrated in its C-terminal tripeptide sequence. KPV (sometimes written as the acetylated Ac-KPV) is that fragment. Because it is short, uncharged in key positions, and relatively stable, KPV is an attractive experimental probe for dissecting melanocortin anti-inflammatory pathways without engaging the full pigmentary receptor cascade.
| Attribute | KPV (research characterization) |
|---|---|
| Sequence | Lys-Pro-Val (C-terminal alpha-MSH 11–13) |
| Parent molecule | Alpha-melanocyte-stimulating hormone (alpha-MSH) |
| Molecular weight | ~342 Da (free tripeptide) |
| Research interest | Anti-inflammatory signaling; gut epithelial models |
| Notable feature | Retains anti-inflammatory activity without melanotropic (pigment) effect |
Investigated Mechanisms of Action
Research suggests KPV acts through more than one route, which is part of why it has drawn sustained laboratory attention. Studies have examined the following pathways in cell and animal models.
NF-κB Pathway Modulation
A central theme in KPV research is attenuation of nuclear factor-kappa B (NF-κB) signaling. In preclinical cell models, KPV has been reported to reduce NF-κB nuclear translocation and downstream transcription of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-alpha. Because NF-κB is a master regulator of inflammatory gene expression, this mechanism is frequently invoked to explain the tripeptide's broad anti-inflammatory profile in research settings.
Melanocortin Receptor and Receptor-Independent Signaling
Full-length alpha-MSH signals through melanocortin receptors (MC1R–MC5R). KPV research is more nuanced: some studies suggest anti-inflammatory effects that appear partly independent of classical melanocortin receptor binding, particularly in epithelial systems. This has made KPV a useful tool for probing where melanocortin anti-inflammatory activity is receptor-mediated versus intracellular. For a deeper treatment of these receptor questions, see our companion article on melanocortins and inflammation.
PepT1-Mediated Epithelial Uptake
One of the most studied aspects of KPV in gut models is its transport into intestinal epithelial cells via the peptide transporter PepT1 (SLC15A1). Research has examined how PepT1 expression on inflamed colonic epithelium may allow KPV to enter cells and act intracellularly on inflammatory signaling. This transporter-mediated uptake is a distinguishing feature of gut-focused KPV studies and a reason the tripeptide is a frequent subject in intestinal inflammation research models.
KPV in Gut-Model Research
Gastrointestinal inflammation models are where KPV research is most concentrated. Investigators have used chemically-induced colitis models (for example, DSS- and TNBS-induced colitis in rodents) and cultured colonic epithelial cell lines to examine KPV's effects on markers of mucosal inflammation. Reported observations in these preclinical models include reduced pro-inflammatory cytokine expression, decreased neutrophil infiltration markers, and improved epithelial barrier readouts. Some studies have also explored oral and nanoparticle-based delivery of KPV in animal models specifically to target inflamed intestinal tissue.
It is important to frame these strictly as findings in research models. They describe biological responses observed in controlled laboratory systems, not clinical outcomes, and they do not support any human or veterinary application.
How KPV Compares to Other Repair-Focused Research Peptides
KPV is often studied alongside other peptides in the healing and tissue-repair research space, each with distinct mechanisms.
- KPV vs. BPC-157 — BPC-157 is a pentadecapeptide studied largely for angiogenesis and tissue-repair signaling, whereas KPV research emphasizes direct anti-inflammatory transcriptional modulation. See our head-to-head KPV vs BPC-157 comparison and the full BPC-157 research guide.
- GHK-Cu — a copper-binding tripeptide studied for extracellular matrix remodeling and skin models; explore the GHK-Cu research guide.
- GLOW blends — KPV sometimes appears in skin-focused research stacks; see the GLOW blend research guide.
All of these sit under our pillar overview of healing and tissue-repair research peptides.
Laboratory Handling and Reconstitution
The following is standard laboratory guidance for preparing research peptides for in-vitro or preclinical work — not usage instructions.
Reconstitution
- Reconstitute lyophilized KPV with sterile or bacteriostatic water, adding the diluent slowly down the vial wall rather than directly onto the powder.
- Gently swirl to dissolve; avoid vigorous shaking, which can shear peptides.
- Prepare working concentrations appropriate to the experimental model and assay system.
Storage and Stability
| State | Typical laboratory storage |
|---|---|
| Lyophilized (sealed) | -20 °C, protected from light and moisture; long-term stable |
| Reconstituted | 2–8 °C for short-term working use |
| Reconstituted (extended) | Aliquot and freeze to minimize freeze-thaw cycles |
Purity and Verification
Reliable KPV research depends on well-characterized material. Every NeuroLabs research peptide, including KPV 10mg, is specified at ≥99% purity and third-party COA-tested, with same-day USA shipping. Reproducible in-vitro and preclinical results require confirmed identity and purity, so reviewing the certificate of analysis (typically HPLC for purity and mass spectrometry for identity) is a routine part of experimental setup.
Summary
KPV is a compact but mechanistically rich research peptide. Its position as the C-terminal tripeptide of alpha-MSH, its modulation of NF-κB-driven inflammatory transcription, and its PepT1-mediated entry into intestinal epithelium together make it a distinctive tool in anti-inflammatory and gut-model research. As with all research chemicals, its value lies in controlled laboratory investigation — never in human or veterinary application.